Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | CA3 | P07451 | 1/20 | 0.51 |
| ▸ | CA6 | P23280 | 1/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29985195 | 1.00 | APP (0.60) | APPCYP2A6CA2PDE3BPDE3A | |
| SCHEMBL566297 | 0.86 | APP (0.58) | APPCYP2A6CA2KDM4EALDH1A1 | |
| SCHEMBL24157660 | 0.81 | APP (0.62) | APPCYP2A6CA2PDE3BPDE3A | |
| SCHEMBL1804423 | 0.80 | APP (0.83) | APPKDM4EALDH1A1HPGDMAOB | |
| SCHEMBL1804421 | 0.80 | APP (0.83) | APPKDM4EALDH1A1HPGDMAOB | |
| SCHEMBL3906481 | 0.80 | GAA (0.57) | APPCYP2A6CA2KDM4EALDH1A1 | |
| SCHEMBL3906474 | 0.80 | GAA (0.57) | APPCYP2A6CA2KDM4EALDH1A1 | |
| SCHEMBL7033540 | 0.79 | KDM4E (0.58) | CYP2A6CA2PDE3BPDE3AKDM4E | |
| SCHEMBL5828704 | 0.78 | APP (0.74) | APPKDM4EALDH1A1HPGDMAOB | |
| SCHEMBL5828701 | 0.78 | APP (0.74) | APPKDM4EALDH1A1HPGDMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-113164458-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | claimed |
| EP-1401453-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-04-06 | — | — | EP | claimed |
| US-20040157828-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-08-12 | — | — | US | claimed |
| EP-1401453-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-31 | — | — | EP | claimed |
| WO-2002092563-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-21 | — | — | WO | claimed |
| EP-4691558-A2 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | University Court of The University of Dundee (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2025-09-25 | — | — | US | disclosed |
| EP-2857018-B1 | Treatment or prophylaxis of proliferative conditions | UNIV COURT OF THE UNIV OF DUNDEE (GB) | 2025-09-03 | — | — | EP | disclosed |
| CN-113999232-B | MAT2A inhibitors | 南京正大天晴制药有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-11851446-B2 | Probes for imaging Huntingtin protein | CHDI FOUNDATION, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20220133698-A1 | a-SYNUCLEIN AGGREGATE BINDING AGENT AND IMAGING METHOD | NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY (JP) | 2022-05-05 | — | — | US | disclosed |
| EP-1501831-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040157828-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-08-12 | — | — | US | disclosed |
| EP-1401453-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003091255-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2002092563-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-21 | — | — | WO | disclosed |
| US-5091533-A | Treating allergies, cardiovascular disorders, inflammation | MERCK FROSST CANADA, INC. (CA) | 1992-02-25 | — | — | US | disclosed |
| EP-0447189-A1 | 5-Hydroxy-2,3-dihydrobenzofuran analogs as leukotriene biosynthesis inhibitors | MERCK FROSST CANADA INC. (CA) | 1991-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851446-B2 | Probes for imaging Huntingtin protein | HTT, HYPK, HSPBP1 | APP 270/4885CYP2A6 4875/4885CA2 2484/4885 |
| US-20220133698-A1 | a-SYNUCLEIN AGGREGATE BINDING AGENT AND IMAGING METHOD | SNCA, HTT, PARK7 | APP 184/4885CYP2A6 4081/4885CA2 3738/4885 |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, BRCA1, UGT1A1 | APP 3745/4885CYP2A6 81/4885CA2 2213/4885 |
| US-20040157828-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | APP 372/4885CYP2A6 1414/4885CA2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.